Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics.

ABSTRACT: Human epidermal growth factor receptor 2 (HER2) is a major driver of disease progression, treatment resistance, and worse survival for patients with various types of cancers, including prostate cancer. However, key bench studies and clinical trials have failed to evaluate the role of HER2 in prostate cancer using racially diverse experimental designs and protocols. This lack of diversity represents what has been the status quo of cancer research in the United States for decades. In the case of prostate cancer, homogenic study designs are problematic as Black men are much more likely to be diagnosed and die from aggressive and incurable forms of the disease. Therefore, the strategic inclusion of biospecimens collected from Black patients as well as the recruitment and enrollment of Black me

SUBMITTER: Mavingire N 

PROVIDER: S-EPMC11476348 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature